In in vivo asthma models, the adoptive transfer of CD141+ DCs or administration of inhaled soluble CD141 resulted in a decline of inflammatory cells, eosinophils and Th2-related cytokines, thus reducing disease severity and progression [75]. The gene discussed is THBD; the disease is asthma.